Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Jakob M RiedlEsther SchwarzenbacherFlorian MoikLena HorvathAntonia GantschniggFelix RennebergFlorian PoschDominik A BarthMichael StotzMartin PichlerStefan HatzlAuthor S Simon Fandler-HöflerPaul GressenbergerThomas GaryPhilipp J JostRichard GreilCihan AyAngela DjananiArmin GergerKonstantin SchlickPublished in: Thrombosis and haemostasis (2021)
Patients with aPC undergoing palliative first-line chemotherapy with FOLFIRINOX or GN face a high risk for VTE/ATE and its diagnosis is linked to worse clinical outcomes. VTE-risk prediction models have limited ability to sub-stratify thrombotic events in this high-risk scenario.